DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+9.69%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.51B
AUM Growth
+$5.51B
(+9.2%)
Cap. Flow
+$169M
Cap. Flow
% of AUM
3.07%
Top 10 Holdings %
Top 10 Hldgs %
54.24%
Holding
168
New
43
Increased
28
Reduced
13
Closed
42
Top Buys
| 1 |
United Therapeutics
UTHR
|
$76.3M |
| 2 |
Merck
MRK
|
$67.9M |
| 3 |
Vera Therapeutics
VERA
|
$54.1M |
| 4 |
Legend Biotech
LEGN
|
$43.3M |
| 5 |
Centene
CNC
|
$27.9M |
Top Sells
| 1 |
Dynavax Technologies
DVAX
|
$67.3M |
| 2 |
Alignment Healthcare
ALHC
|
$59.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
$40.4M |
| 4 |
CMRX
Chimerix, Inc.
CMRX
|
$32.1M |
| 5 |
InMode
INMD
|
$28M |
Sector Composition
| 1 | Healthcare | 89.05% |
| 2 | Real Estate | 0.41% |
| 3 | Financials | 0% |
| 4 | Industrials | 0% |
| 5 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $1.37B | 24.91% | 17,991,024 | – | – |
|
2
Oscar Health
OSCR
$4.31B
| $250M | 4.53% | 11,649,591 -191,227 | -2% | -$4.1M |
|
3
Viatris
VTRS
$12.3B
| $215M | 3.89% | 24,023,907 +32,313 | +0.1% | +$289K |
|
4
Merus
MRUS
$4.98B
| $178M | 3.23% | 3,384,628 +210,700 | +7% | +$11.1M |
|
|
5
Centene
CNC
$14.3B
| $173M | 3.14% | 3,185,370 +513,449 | +19% | +$27.9M |
|
6
ARS Pharmaceuticals
SPRY
$1.15B
| $170M | 3.08% | 9,724,508 -790,149 | -8% | -$13.8M |
|
7
Indivior
INDV
$3.03B
| $156M | 2.83% | 10,567,160 | – | – |
|
|
8
United Therapeutics
UTHR
$13.8B
| $155M | 2.82% | 540,626 +265,400 | +96% | +$76.3M |
|
|
9
Neurocrine Biosciences
NBIX
$13.8B
| $147M | 2.66% | 1,167,802 -321,198 | -22% | -$40.4M |
|
10
Revolution Medicines
RVMD
$7.1B
| $125M | 2.26% | 3,384,072 +66,740 | +2% | +$2.46M |
|
11
Brookdale Senior Living
BKD
$1.83B
| $107M | 1.94% | 15,362,264 -250,000 | -2% | -$1.74M |
|
|
12
Legend Biotech
LEGN
$6.41B
| $105M | 1.91% | 2,962,338 +1,218,783 | +70% | +$43.3M |
|
13
Pfizer
PFE
$141B
| $104M | 1.89% | 4,306,264 +958,968 | +29% | +$23.2M |
|
14
AdaptHealth
AHCO
$1.28B
| $93.4M | 1.7% | 9,904,895 +193,485 | +2% | +$1.82M |
|
15
NewAmsterdam Pharma
NAMS
$2.71B
| $92.6M | 1.68% | 5,115,953 +1,011,996 | +25% | +$18.3M |
|
16
IDEAYA Biosciences
IDYA
$2.15B
| $82.3M | 1.49% | 3,915,311 +647,760 | +20% | +$13.6M |
|
|
17
Vera Therapeutics
VERA
$1.38B
| $78.9M | 1.43% | 3,348,117 +2,298,117 | +219% | +$54.1M |
|
18
Insmed
INSM
$28.8B
| $70.5M | 1.28% | 700,700 +242,700 | +53% | +$24.4M |
|
|
19
Merck
MRK
$210B
| $67.9M | 1.23% | +857,724 | New | +$67.9M |
|
20
Catalyst Pharmaceutical
CPRX
$2.52B
| $62.5M | 1.13% | 2,879,476 -542,673 | -16% | -$11.8M |
|
21
Larimar Therapeutics
LRMR
$310M
| $61.4M | 1.11% | 21,231,974 | – | – |
|
22
Baxter International
BAX
$12.7B
| $58.2M | 1.06% | 1,923,100 | – | – |
|
23
Bio-Rad Laboratories Class A
BIO
$8.06B
| $54.6M | 0.99% | 226,070 | – | – |
|
24
Disc Medicine
IRON
$2.07B
| $48.7M | 0.88% | 919,403 +137,070 | +18% | +$7.26M |
|
25
Alnylam Pharmaceuticals
ALNY
$58.5B
| $47.3M | 0.86% | 145,000 | – | – |
|